Immune escape in breast cancer during in situ to invasive carcinoma transition

Cancer Discovery

Volumn 7, Issue 10, 2017, Pages 1098-1115

  Gil Del Alcazar, Carlos R ^a,b,c   Huh, Sung Jin ^a,b,c,o   Ekram, Muhammad B ^a,b,c   Trinh, Anne ^a,b,c   Liu, Lin L ^a,d   Beca, Francisco ^a,b,c,p   Zi, Xiaoyuan ^e,f   Kwak, Minsuk ^e   Bergholtz, Helga ^g   Su, Ying ^a,b,c,q   Ding, Lina ^a,b,c   Russnes, Hege G ^g   Richardson, Andrea L ^a,b,c,r   Babski, Kirsten ^h   Kim, Elizabeth Min Hui ^h   McDonnell, Charles H ^h   Wagner, Jon ^h   Rowberry, Ron ^h   Freeman, Gordon J ^a,c   Dillon, Deborah ^b,c   Sorlie, Therese ^g   Coussens, Lisa M ⁱ   Garber, Judy E ^a,b,c   Fan, Rong ^e   Bobolis, Kristie ^h   Allred, D Craig ^j   Jeong, Joon ^k   Park, So Yeon ^l   Michor, Franziska ^a,d   Polyak, Kornelia ^a,b,c,m,n   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e Yale University   (United States)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h Sutter Roseville Medical Center   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Yonsei University College of Medicine   (South Korea)

^l Seoul National University Bundang Hospital   (South Korea)

^m BROAD INSTITUTE OF MIT AND HARVARD   (United States)

ⁿ HARVARD STEM CELL INSTITUTE   (United States)

^o XTuit Pharmaceuticals Inc   (United States)

^p STANFORD UNIVERSITY   (United States)

^q IMMUNOGEN INC   (United States)

^r DEPARTMENT OF PATHOLOGY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CXCL1 CHEMOKINE; CXCL13 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 7; KI 67 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; CD3 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PTPRC PROTEIN, HUMAN; RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASE C; TUMOR MARKER;

ARTICLE; BREAST CANCER; CARCINOMA IN SITU; CD3+ T LYMPHOCYTE; CELL TRANSFORMATION; CHROMOSOME 17Q; CHROMOSOME 17Q12; CLINICAL ARTICLE; CLONAL VARIATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION; GENE SET ENRICHMENT ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LEUKOCYTE; NEUTROPHIL; NUCLEIC ACID ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RNA ISOLATION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; BREAST TUMOR; DISEASE EXACERBATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INTRADUCTAL CARCINOMA; PAGET NIPPLE DISEASE; PROCEDURES;

B7-H1 ANTIGEN; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CD3 COMPLEX; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTE COMMON ANTIGENS; RECEPTOR, ERBB-2; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85030685006     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-17-0222     Document Type: Article

References (58)

1. Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol 2016;13:228–41.
2. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6: 24–37.
3. Schedin P, O’Brien J, Rudolph M, Stein T, Borges V. Microenvironment of the involuting mammary gland mediates mammary cancer progression. J Mammary Gland Biol Neoplasia 2007;12:71–82.
4. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16:91–102.
5. Man YG, Sang QX. The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the “protease-centered” hypothesis. Exp Cell Res 2004;301:103–18.
6. Abba MC, Gong T, Lu Y, Lee J, Zhong Y, Lacunza E, et al. A molecular portrait of high-grade ductal carcinoma in situ. Cancer Res 2015;75:3980–90.
7. Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 2008;14: 1956–65.
8. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A 2012;109:2802–7.
9. Lesurf R, Aure MR, Mork HH, Vitelli V, Oslo Breast Cancer Research Centre, Lundgren S, et al. Molecular features of subtype-specific progression from ductal carcinoma in situ to invasive breast cancer. Cell Rep 2016;16:1166–79.
10. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008;14:370–8.
11. Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, et al. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol 2016;29:249–58.
12. Sikandar B, Qureshi MA, Mirza T, Khan S, Avesi L. Differential immune cell densities in ductal carcinoma In-Situ and invasive breast cancer: possible role of leukocytes in early stages of carcinogenesis. Pak J Med Sci 2015;31:274–9.
13. Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, et al. FOXP3- positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat 2013;139:381–90.
14. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Breast Cancer Special Feature: leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A 2011;109:2796–801.
15. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373–80.
16. Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V, et al. The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. Oncoimmunology 2016;5:e1218106.
17. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 2015;522:345–8.
18. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015;21:938–45.
19. Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Wevers E, et al. Tumorinfiltrating gammadelta T lymphocytes predict clinical outcome in human breast cancer. J Immunol 2012;189:5029–36.
20. Sautes-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, et al. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol 2016;7:407.
21. Godec J, Tan Y, Liberzon A, Tamayo P, Bhattacharya S, Butte AJ, et al. Compendium of immune signatures identifies conserved and speciesspecific biology in response to inflammation. Immunity 2016;44: 194–206.
22. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015;12:453–7.
23. Tirosh I, Izar B, Prakadan SM, Wadsworth MH II, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016;352:189–96.
24. Shannon CE. A mathematical theory of communication. The Bell System Technical Journal 1948;27:379–423.
25. Srivastava SK, Robins HS. Palindromic nucleotide analysis in human T cell receptor rearrangements. PLoS ONE 2012;7:e52250.
26. Koning D, Costa AI, Hoof I, Miles JJ, Nanlohy NM, Ladell K, et al. CD8+ TCR repertoire formation is guided primarily by the peptide component of the antigenic complex. J Immunol 2013;190:931–9.
27. Singer M, Wang C, Cong L, Marjanovic ND, Kowalczyk MS, Zhang H, et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell 2016;166:1500–1509.
28. Chauvin JM, Pagliano O, Fourcade J, Sun Z, Wang H, Sander C, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest 2015;125:2046–58.
29. Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V, et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res 2008;68:9532–40.
30. Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, et al. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 2015;6:26483–93.
31. Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol 2016;34:539–73.
32. Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol 2015;45:17–31.
33. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372:311–9.
34. Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, et al. Systemic immunity is required for effective cancer immunotherapy. Cell 2017;168:487–502.
35. Liu J, Blake SJ, Yong MC, Harjunpaa H, Ngiow SF, Takeda K, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 2016;6:1382–99.
36. Ward JP, Gubin MM, Schreiber RD. The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv Immunol 2016;130:25–74.
37. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259–73.
38. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep 2014;6:514–27.
39. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016;7:12150.
40. Pan X, Durrett RE, Zhu H, Tanaka Y, Li Y, Zi X, et al. Two methods for full-length RNA sequencing for low quantities of cells and single cells. Proc Natl Acad Sci U S A 2013;110:594–9.
41. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013;29:15–21.
42. Anders S, Pyl PT, Huber W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics 2015;31:166–9.
43. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139–40.
44. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;15:550.
45. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47.
46. Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res 2014;58:234–9.
47. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545–50.
48. Wang X, Terfve C, Rose JC, Markowetz F. HTSanalyzeR: an R/Bioconductor package for integrated network analysis of high-throughput screens. Bioinformatics 2011;27:879–80.
49. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–64.
50. Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva EV, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods 2015;12:380–1.
51. Cancer Genome Atlas Network.Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61–70.
52. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A 2010;107:16910–5.
53. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015;160:48–61.
54. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013;4:2612.
55. McCulloch CE, Neuhaus JM. Generalized linear mixed models. Wiley Online Library; 2001.
56. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974;19:716–23.
57. Baddeley A, Turner R. Spatstat: an R package for analyzing spatial point patterns. J Stat Softw 2005;12:1–42.
58. Lotwick H, Silverman B. Methods for analysing spatial processes of several types of points. J R Stat Soc B (Methodological) 1982;44:406–13.